» Articles » PMID: 39972382

Modeling-based Design of Adaptive Control Strategy for the Effective Preparation of 'Disease X'

Overview
Publisher Biomed Central
Date 2025 Feb 19
PMID 39972382
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims at exploring a general and adaptive control strategy to confront the rapid evolution of an emerging infectious disease ('Disease X'), drawing lessons from the management of COVID-19 in China. We employ a dynamic model incorporating age structures and vaccination statuses, which is calibrated using epidemic data. We therefore estimate the cumulative infection rate (CIR) during the first epidemic wave of Omicron variant after China relaxed its zero-COVID policy to be 82.9% (95% CI: 82.3%, 83.5%), with a case fatality rate (CFR) of 0.25% (95% CI: 0.248%, 0.253%). We further show that if the zero-COVID policy had been eased in January 2022, the CIR and CFR would have decreased to 81.64% and 0.205%, respectively, due to a higher level of immunity from vaccination. However, if we ease the zero-COVID policy during the circulation of Delta variant from June 2021, the CIR would decrease to 74.06% while the CFR would significantly increase to 1.065%. Therefore, in the face of a 'Disease X', the adaptive strategies should be guided by multiple factors, the 'zero-COVID-like' policy could be a feasible and effective way for the control of a variant with relative low transmissibility. However, we should ease the strategy as the virus matures into a new variant with much higher transmissibility, particularly when the population is at a high level of immunity.

References
1.
Tang B, Bragazzi N, Li Q, Tang S, Xiao Y, Wu J . An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020; 5:248-255. PMC: 7029158. DOI: 10.1016/j.idm.2020.02.001. View

2.
Chia W, Zhu F, Ong S, Young B, Fong S, Bert N . Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021; 2(6):e240-e249. PMC: 7987301. DOI: 10.1016/S2666-5247(21)00025-2. View

3.
Flaxman S, Mishra S, Gandy A, Unwin H, Mellan T, Coupland H . Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020; 584(7820):257-261. DOI: 10.1038/s41586-020-2405-7. View

4.
Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T . The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature. 2020; 584(7820):262-267. DOI: 10.1038/s41586-020-2404-8. View

5.
Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View